Birgit Girshick Purchases 1,514 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) Stock

Charles River Laboratories International, Inc. (NYSE:CRL) COO Birgit Girshick acquired 1,514 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The stock was purchased at an average price of $164.63 per share, with a total value of $249,249.82. Following the transaction, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Charles River Laboratories International Trading Up 0.5 %

CRL stock opened at $163.11 on Friday. The business has a fifty day moving average price of $172.84 and a 200 day moving average price of $188.09. Charles River Laboratories International, Inc. has a fifty-two week low of $150.79 and a fifty-two week high of $275.00. The stock has a market capitalization of $8.34 billion, a price-to-earnings ratio of 1,087.39, a P/E/G ratio of 4.54 and a beta of 1.37. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same period last year, the firm earned $2.46 EPS. Analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Charles River Laboratories International

Hedge funds and other institutional investors have recently made changes to their positions in the company. Versant Capital Management Inc increased its stake in shares of Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after buying an additional 150 shares during the period. Assetmark Inc. increased its stake in shares of Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after buying an additional 173 shares during the period. Pinnacle Bancorp Inc. increased its stake in shares of Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares during the period. Optiver Holding B.V. acquired a new stake in shares of Charles River Laboratories International in the 4th quarter valued at $37,000. Finally, GeoWealth Management LLC increased its stake in shares of Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock valued at $46,000 after buying an additional 190 shares during the period. 98.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CRL has been the subject of a number of research reports. TD Cowen raised their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Evercore ISI increased their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. Bank of America dropped their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Finally, CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price for the company. in a report on Monday, November 18th. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $195.71.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).